Hair loss is a recognized adverse reaction reported in Zepbound clinical trials. The prescribing information notes an association with weight reduction. One possible explanation is telogen effluvium, a form of diffuse hair shedding that can occur after substantial weight loss or other physical stress. However, not all hair loss during tirzepatide treatment is necessarily telogen effluvium, and the exact cause may differ between individuals. This article walks through what the label reports, why rapid weight change can affect hair, and when shedding needs a closer look. It is general education, not medical advice.

What the Zepbound label reports

In the two placebo-controlled weight-reduction trials pooled in the label, hair loss was reported by 5% of people on 5 mg, 4% on 10 mg, and 5% on 15 mg, compared with 1% on placebo [1]. It was more common in women than in men: 7.1% of women taking Zepbound reported it, compared with 0.5% of men [1].

Two other details matter. The label says hair loss in these trials was associated with weight reduction, and no one taking Zepbound stopped treatment because of it [1]. Mounjaro, which also contains tirzepatide, lists alopecia among reports received after approval [2]. Reports like these cannot show how often something happens or prove the drug caused it [2].

Why weight loss can trigger shedding

Hair grows in cycles. Most follicles are growing at any given time, and a smaller share are resting before they shed. A significant physical stressor can push more follicles into the resting phase at once. When those hairs fall out together a few months later, the result is noticeable shedding, called telogen effluvium.

The American Academy of Dermatology lists losing 20 pounds or more among common triggers, alongside childbirth, surgery, high fever, and major stress [3]. It notes that shedding between 50 and 100 hairs a day is normal, and that most people notice excess shedding a few months after the triggering event [3].

This timing is why shedding can feel unrelated to the medication. It often starts well after weight loss is underway.

Other causes worth checking with a provider

Weight change is not the only possibility. Your own provider may want to look at:

  • Inadequate caloric intake, low protein intake, or restrictive dietary patterns, particularly when associated with nausea, vomiting, or substantial appetite suppression.
  • Iron deficiency or anemia, thyroid dysfunction, and selected nutritional deficiencies.
  • Patterned thinning consistent with androgenetic alopecia.
  • Alopecia areata or inflammatory/scarring scalp disorders.
  • Medication changes, recent illness, endocrine changes, and other systemic triggers.

Testing should follow clinical evaluation rather than a fixed laboratory panel. Depending on history and examination, clinicians may consider CBC, ferritin/iron studies, TSH, and targeted nutritional testing. A licensed clinician can determine whether laboratory testing is appropriate based on your symptoms and medical history. Luvo does not currently provide laboratory testing services.

Patients should not independently stop tirzepatide, reduce their dose, or add hair-loss medications or high-dose supplements solely because of shedding.

What tends to help

Telogen effluvium usually settles once the body adjusts. The AAD says excess shedding stops as the body readjusts, and hair tends to regain its normal fullness within six to nine months [3]. If the stressor continues, shedding can last longer [3].

A few practical points come up often:

  • Maintain adequate energy and protein intake during weight reduction. A provider or dietitian can help you decide what that means for you.
  • Treat shedding hair gently. Skip tight styles and harsh chemical treatments for now.
  • Talk with your provider about the pace of your weight change and your dose schedule. Those are clinical decisions that belong with someone who knows your history.

For eating on a GLP-1 medication, see our GLP-1 nutrition guide and our guide to protecting lean mass on GLP-1 medications.

What about compounded tirzepatide?

Compounded tirzepatide is not FDA-approved and is subject to federal and state compounding requirements. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed [4]. FDA recommends use of an FDA-approved drug when it is available and appropriate for the patient. Because the tirzepatide shortage has been resolved, federal law generally restricts pharmacies and outsourcing facilities from routinely producing compounded products that are essentially copies of commercially available FDA-approved tirzepatide products. In limited circumstances, patient-specific compounding may be permissible when applicable legal requirements are satisfied and a patient's clinical needs cannot appropriately be met by an available FDA-approved product.

Data from clinical trials of Zepbound and Mounjaro should not be assumed to establish the safety, effectiveness, quality, potency, or bioequivalence of a compounded product. The hair loss figures above are not data on any compounded formulation. For more, see Important safety information for compounded tirzepatide.

When shedding is not telogen effluvium

The pattern matters. Telogen effluvium is usually diffuse thinning across the scalp. The AAD separates shedding from hair loss, where something stops hair from growing, and points people to a dermatologist when they are unsure which they have [3]. See a provider promptly if you notice:

  • Round or patchy bald spots
  • Itching, burning, pain, redness, or scaling on the scalp
  • A receding hairline or broken hairs
  • Shedding that keeps going long after your weight has stabilized

Like any prescription medication, Zepbound carries risks and possible side effects. The label lists nausea, diarrhea, vomiting, and constipation among the most common, and your provider will review the full picture with you [1]. These are not comprehensive lists of risks or contraindications; patients should review the prescribing information and discuss their medical history with their clinician. See also our overview of tirzepatide side effects and the Zepbound page.

Common questions

Does hair grow back after shedding on Zepbound?
For telogen effluvium in general, the AAD says hair tends to regain its normal fullness within six to nine months once the body readjusts [3]. Recovery varies by person, and patchy or scarring hair loss is a different situation that needs evaluation.

Does lowering the dose help?
There is insufficient evidence that lowering the dose specifically reverses hair shedding. The label links hair loss to weight reduction, not to a specific dose [1]. Whether to change your dose is a decision for your provider.

Is hair loss worse with tirzepatide than with semaglutide?
In the SURMOUNT-5 trial, hair loss was reported in approximately 8.3% of participants receiving tirzepatide and 6.1% receiving semaglutide [5]. Although hair loss was numerically more frequent with tirzepatide, these findings do not establish that one medication directly causes more hair loss than the other. Differences in weight reduction and other patient factors may contribute. More research is needed to clarify the underlying mechanisms. For the semaglutide side, see Does Ozempic cause hair loss?

Next steps

If any of this sounds like what you are dealing with, the next step is a conversation with a licensed provider who can review your history and decide whether treatment makes sense for you. Nothing is prescribed or shipped without that review. Any medication preference you indicate is only a starting point for discussion. A licensed clinician independently determines whether prescription treatment is medically appropriate and, if so, which medication, dose, and treatment plan are appropriate based on your clinical evaluation.

Explore Luvo's Weight Loss Program.

Sources

  1. Zepbound (tirzepatide) prescribing information. Eli Lilly and Company. Revised 08/2026. https://pi.lilly.com/us/zepbound-uspi.pdf
  2. Mounjaro (tirzepatide) prescribing information. Eli Lilly and Company. Revised 04/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866Orig1s052lbl.pdf
  3. American Academy of Dermatology. "Do you have hair loss or hair shedding?" Accessed 2026-10-26. https://www.aad.org/public/diseases/hair-loss/insider/shedding
  4. U.S. Food and Drug Administration. "FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs." Content current as of 2026-06-15. Accessed 2026-10-26. https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs
  5. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26-36. doi:10.1056/NEJMoa2416394. https://www.nejm.org/doi/10.1056/NEJMoa2416394

This article is for general educational purposes and is not medical advice. It is not a substitute for a conversation with a licensed healthcare provider about your own health. Prescription treatments require provider review and approval. Individual results vary.

Compounded medications are prepared by a licensed compounding pharmacy and are not FDA-approved. The FDA does not evaluate compounded drugs for safety, effectiveness, or quality.

This article does not provide calorie, macronutrient, or portion targets. If tracking food or restricting intake causes you distress, bring it up with a clinician before making changes.

All brand names are the trademarks of their respective owners. Luvo Health is not affiliated with, endorsed by, or sponsored by any of them.